Everest Medicines Begins Operations at mRNA Facility
Following numerous successful trial runs, vaccine production is expected to reach 700 million.
Everest Medicines, a biopharmaceutical manufacturing company, has officially opened a new $130 million plant, after multiple successful mRNA trial production runs at the aforementioned site based in Jiashan, China. According to the company, this production facility is a critical part of establishing a full industrial value chain of research, clinical development, manufacturing, and commercialization.
Spanning over 624,000 square feet, the complex is designed with an annual production capacity of 700 million vaccine doses. Trial runs—which had taken place since the facility commenced operations late last year—have met company expectations.
"Over the past few years, mRNA technology has attracted widespread attention, due to the COVID-19 pandemic outbreak and surging demand for COVID-related vaccines,” says Rogers Yongqing Luo, CEO of Everest Medicines. “Thanks to its unique mechanism, mRNA technology has shown broad potential and clinical value in multiple disease prevention and treatment areas. We are proud to have established an advanced production facility within such a short time frame.”
